Rifampin

CHEMBL374478 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

822.9 g/mol

LogP

4.9

Phase

4

A broad-spectrum antibiotic and a cornerstone of tuberculosis treatment, used in combination regimens to kill Mycobacterium tuberculosis. It works by inhibiting bacterial RNA synthesis and is also used to prevent infections caused by Neisseria meningitidis.

Moleküler Ağırlık

822,9000 g/mol

LogP

4,90

TPSA

220,00 Å²

Lipinski RO5

Başarısız

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Hematology Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Oncology Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

InChI

InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

Molecular Formula

C43H58N4O12

HBD / HBA

6 / 15

Döndürülebilir Bağlar

5

Ağır Atomlar

59

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A broad-spectrum antibiotic and a cornerstone of tuberculosis treatment, used in combination regimens to kill Mycobacterium tuberculosis. It works by inhibiting bacterial RNA synthesis and is also used to prevent infections caused by Neisseria meningitidis.

Yes, Rifampin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL374478. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135398735. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Rifampin PillFYI'da

Yapı

Hızlı Veriler

Formül: C43H58N4O12
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.